past
year
number
new
human
polyomavirus
ki
wu
human
polyomaviru
human
polyomaviru
trichodysplasia
spinulosa
viru
tsv
human
polyomaviru
merkel
cell
polyomaviru
mcpyv
discov
alland
et
al
gaynor
et
al
feng
et
al
schowalt
et
al
van
der
meijden
et
al
scuda
et
al
mcpyv
discov
digit
transcriptom
subtract
human
skin
cancer
merkel
cell
carcinoma
feng
et
al
find
mcpyv
human
merkel
cell
carcinoma
suggest
role
viru
causat
cancer
confirm
research
abl
detect
mcpyv
dna
germani
kassem
et
al
europ
becker
et
al
north
america
garneski
et
al
franc
foulongn
et
al
merkel
cell
carcinoma
specimen
recent
studi
report
detect
mcpyv
lymphoid
tissu
sharp
et
al
respiratori
specimen
bialasiewicz
et
al
goh
et
al
kantola
et
al
et
al
aim
studi
determin
preval
mcpyv
respiratori
specimen
collect
immunocompet
immunocompromis
patient
evalu
possibl
contribut
viru
respiratori
diseas
alon
combin
respiratori
virus
total
specimen
patient
respiratori
tract
diseas
randomli
select
among
nasopharyng
aspir
submit
clinic
virolog
laboratori
manchest
royal
infirmari
octob
februari
specimen
store
use
specimen
studi
accord
current
royal
colleg
pathologist
guidelin
http
wwwrcpathorgindexasp
diagnost
specimen
specimen
associ
clinic
data
collect
specimen
anonymis
renumb
remov
patient
identifi
data
use
studi
specimen
extract
use
viru
spin
kit
qiagen
crawley
west
sussex
uk
follow
manufactur
instruct
allow
detect
rna
virus
viral
rna
revers
transcrib
complementari
dna
cdna
util
apppli
biosystem
taq
revers
transcript
kit
appli
biosystem
warrington
uk
random
hexam
prime
prior
pcr
amplif
use
assay
influenza
b
c
virus
parainfluenza
virus
type
pcr
respiratori
syncyti
viru
rsv
type
b
human
bocaviru
hbov
human
metapneumoviru
hmpv
detect
polyomavirus
ki
wu
bk
jc
lpv
assay
dna
pcr
util
previous
describ
abedi
kiasari
et
al
abedi
kiasari
nucleic
acid
extract
nasopharyng
aspir
use
qiaampdna
blood
biorobot
mdx
kit
qiagen
accord
manufactur
instruct
store
use
avoid
process
taken
separ
locat
pcr
analysi
pcr
assay
standard
precaut
avoid
amplicon
nucleic
acid
contamin
taken
sampl
test
individu
ad
nucleic
acid
master
mix
reaction
mix
contain
pmol
primer
dntp
pcr
buffer
u
amplitaq
gold
dna
polymeras
appli
biosystem
pcr
assay
perform
genamp
pcr
system
thermal
cycler
appli
biosystem
sampl
subject
cycl
min
follow
cycl
min
min
min
final
extens
min
neg
control
includ
experi
sampl
initi
analyz
use
lt
pcr
assay
describ
feng
et
al
plasmid
pgemt
contain
larg
antigen
mcpyv
kindli
provid
dr
vincent
foulongn
univers
montpelli
montpelli
franc
also
use
posit
control
amplifi
product
analyz
electrophoresi
agaros
gel
visual
ultraviolet
uv
light
compar
size
low
rang
quantit
dna
ladder
invitrogen
life
technolog
paisley
uk
strongli
posit
mcpyv
sampl
dna
copi
use
posit
control
subsequ
experi
pcr
assay
confirm
result
posit
specimen
subject
second
pcr
analysi
use
primer
target
differ
genom
region
mcpyv
pcr
assay
feng
et
al
use
tenfold
serial
dilut
posit
control
sensit
lt
pcr
pcr
determin
respect
posit
defin
definit
establish
result
pcr
assay
agre
sequenc
carri
use
big
dye
termin
cycl
sequenc
kit
appli
biosystem
abi
genet
analyz
appli
biosystem
sequenc
assembl
analyz
edit
use
sequench
softwar
version
gene
code
corpor
ann
arbor
mi
nucleotid
sequenc
align
clustal
w
univers
colleg
dublin
eir
phylogenet
analysi
perform
sequenc
deriv
region
phylogenet
tree
visual
use
molecular
evolutionari
genet
analysi
mega
version
tamura
et
al
bootstrap
test
replic
use
estim
confid
branch
pattern
tree
median
age
patient
month
mean
year
rang
year
male
femal
ratio
specimen
test
studi
two
group
patient
group
consist
nasopharyng
aspir
sampl
obtain
paediatr
patient
immunocompet
age
rang
year
mean
month
median
month
group
ii
includ
nasopharyng
aspir
sampl
obtain
adult
patient
either
solid
organ
transplant
patient
patient
treat
leukemia
age
rang
year
mean
year
median
year
group
upper
lower
respiratori
infect
sixteen
sampl
produc
posit
result
lt
pcr
assay
confirm
pcr
assay
posit
sampl
investig
bidirect
sequenc
assay
amplif
product
age
distribut
patient
mcpyv
infect
shown
tabl
mcpyv
identifi
sampl
children
age
day
month
mean
month
immunocompet
mcpyv
dna
also
detect
sampl
taken
patient
age
year
mean
year
immunosuppress
tabl
ii
incid
mcpyv
case
show
weekli
variat
studi
period
evid
higher
frequenc
detect
virus
winter
period
three
mcpyv
posit
case
n
hmpv
n
doubl
hbov
n
detect
none
sampl
posit
influenza
b
c
virus
virus
type
rsv
type
b
bkv
jcv
lpv
kiv
wuv
sequenc
analysi
mcpyv
pcr
product
assay
reveal
homolog
publish
sequenc
virus
genbank
ncbi
feng
et
al
sequenc
product
suffici
qualiti
use
phylogenet
analysi
phylogenet
analysi
reveal
high
level
ident
mcpyv
isol
genbank
access
number
base
gene
sequenc
bp
strain
found
studi
cluster
dna
sequenc
homolog
fig
mcpyv
dna
found
nasopharyng
aspir
sampl
obtain
patient
respiratori
tract
diseas
determin
pcr
assay
lt
consid
sampl
posit
pcr
assay
produc
posit
result
preval
report
could
therefor
underestim
similar
discord
lt
posit
mcpyv
result
report
feng
et
al
bialasiewicz
et
al
goh
et
al
variat
detect
rate
could
due
amplif
lt
pcr
lower
sensit
pcr
assay
sampl
unlik
sampl
collect
year
differ
hospit
contamin
plasmid
templat
also
unlik
water
control
consist
neg
assay
easili
reproduc
frequenc
mcpyv
detect
studi
higher
found
australia
bialasiewicz
et
al
finland
kantola
et
al
lower
found
sweden
goh
et
al
also
preval
mcpyv
sampl
collect
higher
found
kiv
wuv
respect
abedi
kiasari
et
al
although
sampl
test
studi
collect
autumn
winter
month
clear
peak
infect
perhap
suggest
lack
season
pattern
detect
mcpyv
associ
respiratori
viru
infect
sequenc
data
posit
specimen
show
mcpyv
found
respiratori
specimen
similar
sequenc
virus
identifi
within
merkel
cell
carcinoma
feng
et
al
despit
limit
number
sequenc
analyz
minim
variat
suggest
stabil
sequenc
viru
genom
global
similar
viru
presenc
mcpyv
respiratori
tract
suggest
respiratori
tract
may
rout
transmiss
jc
bk
suspect
transmit
inhal
occasion
detect
respiratori
sampl
goudsmit
et
al
sandler
et
al
rel
high
rate
respiratori
virus
observ
studi
sever
altern
respiratori
pathogen
includ
rhinoviru
adenoviru
coronaviru
enteroviru
test
thu
proport
possibl
higher
mcpyv
howev
viru
detect
children
evid
respiratori
tract
diseas
still
possibl
respiratori
system
could
primari
target
mcpyv
viru
contribut
respiratori
tract
diseas
suscept
children
present
studi
specimen
immunocompet
patient
specimen
immunocompromis
patient
test
group
either
lower
upper
respiratori
diseas
immunocompet
immunocompromis
group
found
mcpyv
posit
posit
sampl
immunocompet
group
children
age
rang
month
fact
mcpyv
posit
patient
immunocompromis
year
age
suggest
earli
acquisit
mcpyv
also
patient
age
day
found
mcpyv
posit
perhap
suggest
potenti
vertic
transmiss
rout
mcpyv
mother
infant
could
howev
determin
whether
babi
mother
viral
infect
whether
babi
viraemia
immunocompromis
group
four
mcpyv
posit
patient
older
age
group
year
higher
rate
mcpyv
detect
elderli
immunosuppress
patient
present
studi
suggest
associ
mcpyv
alter
immun
statu
may
mirror
similar
pattern
reactiv
bkv
jcv
seen
leukemia
transplant
patient
et
al
examin
sampl
control
group
patient
without
respiratori
diseas
immunocompet
immunosuppress
may
shed
light
associ
mcpyv
diseas
studi
concern
role
mcpyv
respiratori
diseas
pathogenesi
mcpyv
relationship
immunosuppress
clearli
warrant
